GlaxoSmithKline' popular medicine Zinetac has Ranitidine which is a Carcinogen
In 7 years, from 2011-2017, the FDA received more than 5.4Mn reports of side effects of drugs prescribed by the doctors; this also included 1Mn death1. Indeed, prescription drugs are often accompanied by undesirable secondary effects1. Manufacturers need to disclose the potential side effects so that the prescribing doctor and patient can weigh the benefits against the risks1.
GlaxoSmithKline's total GHG emission (scope 1,2 & 3) in 2019 were 5.77 million tonnes
Globally 50 billion tonnes of CO2 equivalent of greenhouse gas (GHG) is emitted every year1. According to a study published in the Journal of Cleaner Production in 2015 pharmaceutical industry contribution to GHG emission was bigger than that of the automotive industry2. Although the pharmaceutical sector is 28% smaller it is 13% more polluting than the automotive sector2. In order to meet the reduction targets of the Paris Agreement the pharmaceutical industry will have to reduce its emission by 58.6% by 20252.
The total waste generated by GlaxoSmithKline in 2019 was 117,000 tonnes
Globally almost 100,000 tonnes of pharmaceutical products are manufactured every year1. According to the WHO, 85% of pharmaceutical waste is non-hazardous, and 15% is hazardous waste2. Improper disposal of unused medicines accounts for 10%, and the production process accounts for 2% of the total waste generated3.
GlaxoSmithKline consumed 3,995 GWh of energy in 2019 and only 5% was from renewable sources
Fossil fuel is the source of 80% of the energy produced worldwide1. The global energy consumption in 2019 was 160 million GWh1. Renewable energy withholds the production of greenhouse gases, particularly CO2, that causes global warming3. The 70% energy requirement of the industrial sector is fulfilled by non-renewable sources4.
GlaxoSmithKline’s high pricing makes medicines inaccessible for lupus and asthma patients
The promotion of affordable and fair price intervention is essential for achieving universal health coverage1. However, companies are exploiting the patients by charging prices that are not affordable1. This is a concern for the people who have chronic diseases, including asthma and lupus9;p1. Globally, lupus affects 40-100 individuals out of every 100,000 people2, and asthma affects over 339 million people3.